PSM Antibody (YPSMA-1): sc-59674
- PSM Antibody (YPSMA-1) is a mouse monoclonal IgG2b κ, cited in 8 publications, provided at 100 µg/ml
- raised against crude membrane protein preparation from pooled human prostate malignant carcinoma
- recommended for detection of PSM of human origin by WB, IP, IF and IHC(P)
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for PSM Antibody (YPSMA-1). This work is in progress.
QUICK LINKS
SEE ALSO...
PSM Antibody (YPSMA-1) is a mouse monoclonal IgG2b antibody that detects prostate-specific membrane antigen (PSM) in human samples through western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Anti-PSM antibody (YPSMA-1) recognizes an integral membrane protein that plays a crucial role in prostate cancer progression, showing overexpression in malignant tumors while maintaining low levels in normal tissues. This specificity makes PSM a valuable biomarker for diagnosing prostate cancer, as well as for monitoring disease progression and response to therapy. PSM monoclonal antibody (YPSMA-1) targets proteins primarily located on prostate cancer cell surfaces, enabling targeted therapeutic strategies like antibody-drug conjugates that selectively deliver cytotoxic agents to cancerous cells while sparing healthy tissues. PSM (YPSMA-1) antibody helps detect proteins involved in cellular processes, including cell adhesion and signaling, which are critical for tumor growth and metastasis. Accurate detection and quantification of PSM using PSM (YPSMA-1) monoclonal antibody enhances research and clinical efforts aimed at improving outcomes for patients with prostate cancer.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
PSM Antibody (YPSMA-1) References:
- Radiolabeled prostate-specific membrane antigen small-molecule inhibitors. | Will, L., et al. 2017. Q J Nucl Med Mol Imaging. 61: 168-180. PMID: 28217987
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. | Eiber, M., et al. 2017. J Nucl Med. 58: 67S-76S. PMID: 28864615
- Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. | Hofman, MS., et al. 2018. Radiographics. 38: 200-217. PMID: 29320333
- Prostate-specific membrane antigen-targeted endoradiotherapy in metastatic prostate cancer. | Lawal, IO., et al. 2020. Curr Opin Urol. 30: 98-105. PMID: 31644433
- Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate Cancer. | Weber, M., et al. 2021. Eur Urol Focus. 7: 279-287. PMID: 33483289
- Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond. | Nauseef, JT., et al. 2021. Eur Urol Focus. 7: 254-257. PMID: 33648895
- Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer. | Sun, M., et al. 2021. Curr Oncol Rep. 23: 59. PMID: 33778927
- Prostate-specific membrane antigen-mediated theragnostics in prostate cancer. | Jeong, SH. and Kwak, C. 2021. Investig Clin Urol. 62: 497-499. PMID: 34488249
- Metamorphosis of prostate specific membrane antigen (PSMA) inhibitors. | Nikfarjam, Z., et al. 2022. Biophys Rev. 14: 303-315. PMID: 35340601
- Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches. | Hawkey, NM., et al. 2022. Clin Adv Hematol Oncol. 20: 227-238. PMID: 35389387
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PSM Antibody (YPSMA-1) | sc-59674 | 100 µg/ml | $322.00 |